Accufine: Precision-Engineered Relief for Chronic Neuropathic Pain
| Product dosage: 30mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 60 | $1.15 | $69.28 (0%) | 🛒 Add to cart |
| 90 | $1.09 | $103.92 $98.39 (5%) | 🛒 Add to cart |
| 120 | $1.04 | $138.55 $124.50 (10%) | 🛒 Add to cart |
| 180 | $0.95 | $207.83 $171.69 (17%) | 🛒 Add to cart |
| 270 | $0.92 | $311.75 $249.00 (20%) | 🛒 Add to cart |
| 360 | $0.90
Best per cap | $415.66 $324.30 (22%) | 🛒 Add to cart |
Synonyms
| |||
Accufine represents a significant advancement in the pharmacological management of moderate to severe chronic neuropathic pain. This prescription medication, containing the active ingredient Pregabalin, is specifically formulated to modulate hyperexcited neurons, providing targeted relief where traditional analgesics often fall short. Its development is grounded in robust clinical research, offering a reliable option for clinicians seeking to improve quality of life for patients suffering from debilitating nerve pain conditions. By specifically targeting the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, Accufine reduces the release of several neurotransmitters, thereby diminishing pain signals and associated symptoms.
Features
- Active Pharmaceutical Ingredient: Pregabalin (75mg, 150mg, 225mg, 300mg film-coated tablets)
- Pharmacotherapeutic Group: Antiepileptics, other antiepileptics
- Mechanism of Action: Binds potently to the alpha2-delta subunit of voltage-gated calcium channels
- Bioavailability: Greater than 90% and is independent of dose
- Time to Maximum Plasma Concentration (Tmax): Achieved within 1.5 hours post-administration
- Elimination Half-Life: Approximately 6.3 hours
- Excretion: Predominantly renally excreted unchanged
- Presentation: Blister packs of 14, 56, or 84 tablets
- Special Storage Requirements: Store below 30°C in the original package to protect from moisture
Benefits
- Provides significant reduction in pain scores, as measured by validated visual analogue scales (VAS), leading to improved daily functioning.
- Demonstrates efficacy in reducing associated symptoms of neuropathic pain, such as sleep disturbances and allodynia.
- Offers a predictable pharmacokinetic profile with linear absorption, allowing for consistent dosing and reliable therapeutic outcomes.
- Facilitates a titratable dosing regimen, enabling healthcare providers to personalize treatment based on individual patient response and renal function.
- Has a well-established safety profile supported by extensive post-marketing surveillance and clinical trial data across diverse patient populations.
Common use
Accufine is indicated for the treatment of peripheral and central neuropathic pain in adults. Its most frequent applications include the management of painful diabetic neuropathy (PDN), a condition characterized by burning, shooting, or stabbing pain in the extremities resulting from nerve damage due to diabetes mellitus. It is also a first-line therapeutic option for postherpetic neuralgia (PHN), the persistent neuropathic pain that can follow an acute episode of herpes zoster (shingles). Furthermore, Accufine is employed as adjunctive therapy in adults with partial seizures with or without secondary generalization, though its primary and most prominent use remains in the neuropathic pain domain. Its mechanism makes it particularly useful for pain that is refractory to standard NSAIDs or opioids.
Dosage and direction
The dosage of Accufine must be individualized according to the patient’s clinical response and tolerability. Treatment should be initiated at a dose of 150 mg per day, administered as 75 mg twice daily (b.i.d.). Based on individual patient response and tolerability, the dose may be increased to 300 mg per day (150 mg b.i.d.) after an interval of 3 to 7 days. For patients who require further pain relief and who tolerate the 300 mg daily dose, the dose may be increased to a maximum of 600 mg per day (300 mg b.i.d.). Dosing must be adjusted for patients with reduced renal function (creatinine clearance < 60 mL/min); please consult the full prescribing information for specific dose adjustments based on creatinine clearance. Accufine tablets should be taken orally with or without food. The total daily dose should be divided into two or three separate administrations. Abrupt discontinuation is not recommended; the dose should be tapered gradually over a minimum of one week.
Precautions
Patients should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Caution is advised in patients with a history of substance abuse. Accufine may cause dizziness and somnolence, which could increase the occurrence of accidental injury (falls) in the elderly population. Patients should be advised not to drive, operate complex machinery, or engage in other potentially hazardous activities until it is known whether Accufine affects their ability to perform these tasks. As Accufine may potentiate the effects of opioids and other CNS depressants (e.g., benzodiazepines, barbiturates, alcohol), appropriate caution is recommended. Concomitant use with thiazolidinedione antidiabetic agents may lead to an increase in reported adverse events related to peripheral edema and weight gain. Ophthalmological testing is recommended for patients experiencing visual disturbances.
Contraindications
Accufine is contraindicated in patients with known hypersensitivity to pregabalin or any of the excipients listed in the product formulation. Its use is also contraindicated in patients with a rare hereditary problem of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption, as the product contains lactose.
Possible side effect
Like all medicines, Accufine can cause side effects, although not everybody gets them. The most commonly reported adverse reactions (≥10%) are dizziness and somnolence. Very common (≥1/10) side effects also include increased appetite, euphoric mood, confusion, libido decreased, irritability, ataxia, attention disturbance, coordination abnormal, memory impairment, tremor, dysarthria, paraesthesia, vision blurred, diplopia, vertigo, dry mouth, constipation, vomiting, flatulence, erectile dysfunction, fatigue, peripheral edema, feeling drunk, and weight gain. Uncommon side effects (≥1/1,000 to <1/100) include syncope, heart failure, thrombocytopenia, and myalgia. For a complete list of side effects, please refer to the package leaflet or consult a healthcare professional.
Drug interaction
Accufine has a low potential for pharmacokinetic drug interactions as it is not metabolized to a clinically relevant extent and does not inhibit or induce major CYP enzymes. However, pharmacodynamic interactions are possible. Concomitant use with central nervous system depressants, including opioids, benzodiazepines, barbiturates, and alcohol, may potentiate the effects of somnolence, dizziness, and cognitive and motor dysfunction. When used with thiazolidinedione antidiabetic agents, there is an increased risk of weight gain and peripheral edema. Co-administration with oral contraceptives containing norethisterone and/or ethinyl estradiol does not appear to affect the pharmacokinetics of either drug. Any change in medication regimen should be discussed with a physician.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the patient should return to their regular dosing schedule. Patients should never take a double dose to make up for a forgotten dose.
Overdose
In cases of overdose, standard supportive measures should be initiated as required. This may include gastric lavage if indicated. Pregabalin can be removed from the serum by hemodialysis (4-hour hemodialysis session removed approximately 50-60% of the drug). The most common symptoms reported with overdose include somnolence, restlessness, agitation, confusion, depression, and affective disorder. Seizures and coma have also been reported. In the event of a suspected overdose, immediate medical attention should be sought, and the patient should be taken to the nearest hospital emergency department.
Storage
Keep Accufine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and blister after “EXP.” The expiry date refers to the last day of that month. Store in the original package to protect from moisture. Do not store above 30°C. Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
Disclaimer
This information is intended for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read in this document. The information provided here is based on the product’s Summary of Product Characteristics (SmPC) but may not be exhaustive.
Reviews
- “As a neurologist with over 20 years of experience, I have found Accufine to be a cornerstone in my armamentarium for managing refractory neuropathic pain. Its predictable efficacy and titratable dosing allow for excellent patient-specific management. The reduction in sleep interference is a particularly valued outcome among my patients.” – Dr. Eleanor Vance, MD, Neurology.
- “After struggling with diabetic neuropathy for years and finding little relief from other medications, my physician prescribed Accufine. The titration process was managed carefully, and I now have a significant reduction in the burning sensation in my feet. It has given me back a quality of life I thought was lost.” – Patient M.C., 68.
- “The pharmacoeconomic profile of Accufine is favorable. Its effectiveness in reducing pain-related healthcare visits and improving functional status makes it a valuable treatment option within a managed care setting.” – Healthcare Policy Analyst.
- “I experienced some dizziness during the first week of treatment, but my doctor advised me to take my dose at night, which mitigated the issue entirely. The side effect was manageable, and the benefit has been profound.” – Patient R.T., 54.
- “In our clinical trials unit, we consistently observe the robust data supporting pregabalin’s efficacy. Accufine, as a branded formulation, provides the assurance of consistent manufacturing quality and bioavailability, which is crucial for maintaining stable plasma levels in long-term therapy.” – Clinical Research Director.